H. pylori is a common prevalent gastric pathogen that can lead to serious issues like ulcers and even gastric cancer. While traditional bismuth quadruple therapy (BQT) works well, it has limitations, including antibiotic resistance and side effects.

Wecare Probiotics announced the successful conclusion of its pivotal seminar, "Clinically Validated + Potency Guaranteed + Officially Registered: Driving Probiotic Products Back to Fundamentals."

Ulcerative colitis (UC) is a lifelong condition marked by painful flares, limited drug options, and a gut microbiota in disarray. This 21-day trial set out to test whether a daily dose of Lactobacillus acidophilus LA85 could deliver measurable relief in the DSS treated mouse model with UC.

​Wecare Probiotics' Bifidobacterium animalis subsp. lactis BLa80 has made history as the first probiotic strain from mainland China to enter the Infant Whitelist with both self-affirmed GRAS and FDA GRAS status.

The global health landscape is undergoing a significant transformation, marked by a dramatic increase in overweight and obesity rates. According to the World Health Organization (WHO), in 2025 this year, a staggering one in eight people worldwide were living with obesity.

Wecare Probiotics, as a leading technological innovator, is excited to announce the significant potential of its flagship probiotic strain, Lacticaseibacillus Rhamnosus LRa05, in advancing women's health.